Home › Soft Tissue Sarcoma › NCT00579566
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * All patients with known or suspected sarcoma who will have or have had tissue removed for therapeutic or diagnostic purposes. * Patients will be entered without preference for any particular racial/ethnic group or gender. * Patients may have received prior hormonal therapy, cytotoxic chemotherapy, irradiation, immunotherapy or surgical therapy. * Tissue specimens must be large enough in quantity to allow routine pathologic analysis, with the research laboratory specimen removed from the residual specimen, which would otherwise be discarded. Optimal tissue amounts for snap freeze: Core biopsy - 2 tissue cores Incisional biopsy- 0.5 to 1.5 grams Resected sarcoma specimen- 1.0 to 50 grams depending on size of specimen Normal fat or muscle tissue - 0.5 to 4.0 grams (if available from resected sarcoma specimen) Optimal tissue amounts for RNA later Core biopsy - 2 tissue cores Incisional biopsy- 30 mg (three 3 x 3 x 3 mm cubes) Resected sarcoma specimen - 30 mg (three 3 x 3 x 3 mm cubes) Normal fat or muscle tissue - 30 mg (three 3 x 3 x 3 mm cube Exclusion Criteria: \- None
About the study
The purpose of this study is to study normal and sarcoma cells. To study these cells we need to have human tissue. You will be having or have already had a procedure to remove tissue. We would like to use some of this tissue. We will use it for laboratory studies on the diagnosis,behavior and treatment of sarcoma. We will perform an extensive analysis of your samples. We will only use extra tissue left over after all needed testing has been done or remove an additional small amount of tissue if you are having a biopsy. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of sarcoma.
What is being tested
- Specimen protocol (other)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 3,000 · Started: 2002-06
Contact the study team
- Samuel Singer, MD · Phone: 212-639-2940
Official record on ClinicalTrials.gov — NCT00579566
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.